Speaker Profile

M.D., Ph.D., Chief Scientific Officer and President of Regeneron Laboratories

Dr. Yancopoulos joined Regeneron in 1989 as its Scientific Founder. In the 1990s, Dr. Yancopoulos was the 11th most highly cited scientist in the world, and in 2004 he was elected to both the National Academy of Sciences and the American Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and developer of Regeneron’s four FDA-approved drugs – PRALUENT® (alirocumab) Injection, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection – as well as of Regeneron’s foundational technologies for target and drug development, such as its proprietary TRAP technology, VelociGene® and VelocImmune®. These technologies have produced Regeneron’s robust pipeline of fully human antibodies targeting eye disease, rheumatoid arthritis, atopic dermatitis, asthma, pain, cancer and infectious diseases. In 2014, Dr. Yancopoulos and his team launched the Regeneron Genetics Center, a major new initiative in human genetic research that has already sequenced exomes from over 100,000 people.

Session Abstract – PMWC 2018 Silicon Valley

Session Synopsis: Building robust databases via which to analyze genomic data and making meaningful associations between genes and diseases will ultimately lead to new drug targets and the ability to help guide the development of new therapeutics. The different presenters in this session will illustrate various ways of new drug design that are based on recent technological advancements and genetic insights.

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

View the top 3 talks from PMWC here (password: top-videos).